PharmacoEconomics & Outcomes News 792, p27 - 2 Dec 2017 Severity of AD increases resource use and costs in France Increased severity of Alzheimer’s disease (AD) appears to increase resource use and societal costs in France, according to findings of the Eli Lilly and Co- funded study published in Value in Health. This analysis of data from the French cohort of the observational GERAS study investigated resource use and societal costs over 18 months in 419 community- dwelling patients with AD, and the effects of cognitive decline on patient costs and societal costs. Patients were enrolled between October 2010 and September 2011. Cumulative total societal costs over the 18-month period were significantly higher in patients with moderately severe or severe AD than in those with mild or moderate AD (€44 171 vs €24 140 and €34 287, respectively; p<0.001). Caregiver informal care accounted for 51%–53% of total societal costs, ranging from €12 556 in patients with mild AD to €22 704 in those with moderately severe or severe AD. Cognitive decline (defined as institutionalisation or reduction in Mini-Mental State Examination score of ≥3 points) was associated with a 12.5% increase in costs (p=0.02). While caregiver time differed significantly between AD severity groups (p<0.001), caregiver time per month increased in all severity groups at 6, 12 and 18 months. "Increasing severity of AD dementia in France is associated with increased total societal and patient costs, and clinically meaningful cognitive decline is associated with increased costs," concluded the authors. "This study confirms the quantity and importance of the caregiver burden and costs associated with AD . . . Health and social policies should further focus on supporting the caregiver," they said. * 2010 euros Rapp T, et al. Resource Use and Cost of Alzheimer’s Disease in France: 18-Month Results from the GERAS Observational Study. Value in Health : 11 Nov 2017. Available from: URL: https://doi.org/10.1016/j.jval.2017.09.019 803286172 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera